Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples
| Autor: | Ka-Yi Leung, Kwok-Hung Chan, Danlei Liu, Yu-Jing Fan, Ricky-Ruiqi Zhang, Ivan Hung, Honglin Chen, Kwok-Yung Yuen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Medicine (General)
live virus microneutralization Coronavirus disease 2019 (COVID-19) biology business.industry SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clinical Biochemistry COVID-19 Breakthrough infection medicine.disease_cause Virology Article Vaccination R5-920 surrogate neutralization assay biology.protein Medicine Microneutralization Assay neutralizing antibodies Antibody business Neutralizing antibody Coronavirus |
| Zdroj: | Diagnostics, Vol 11, Iss 1757, p 1757 (2021) Diagnostics Volume 11 Issue 10 |
| ISSN: | 2075-4418 |
| Popis: | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibody (NAb) production is a crucial humoral response that can reduce re-infection or breakthrough infection. The conventional test used to measure NAb production capacity levels is the live virus-neutralizing assay. However, this test must be conducted under biosafety level-3 containment. Pseudovirus or surrogate NAb tests, such as angiotensin-converting enzyme 2 inhibition tests, can be performed under level-2 containment. The aim of this study was to evaluate the performance of a surrogate SARS-CoV-2 NAb assay (sNAb) using samples from naturally infected individuals and vaccine recipients in comparison with the live virus microneutralization assay (vMN). Three hundred and eighty serum samples which were collected from 197 patients with COVID-19, 96 vaccine recipients and 84 normal individuals were analyzed. Overall, the sensitivity, specificity, positive predictive value, and negative predictive value of the sNAb (iFlash-2019-NAb assay, Shenzhen, China) were 97.9%, 94.9%, 98.2%, and 93.8%, respectively. Agreement for the assay relative to vMN for naturally infected individuals and vaccine recipients were 98.5% and 93.9%, respectively. A correlation analysis between sNAb and the vMN for both of these groups yielded an R2 value of 0.83. The iFlash RBD NAb assay is found to be sensitive and reliable for neutralizing antibody measurement in patients with the 2019 coronavirus disease and those who have been vaccinated against it. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|